Good manufacturing practices (GMP) regulations ensure consistency and quality in pharmaceutical manufacturing. GMP covers facilities, equipment, personnel, production, packaging and quality control. Key requirements include designated clean areas for operations, qualified personnel, documented procedures, process validation, environmental monitoring, component testing and record keeping. GMP aims to prevent contamination and errors through strict quality standards at all stages of production.
Hygiene standards and procedures usually described as Good Hygienic Practices (GHP) or Good Manufacturing Practices (GMP), have been in place for many years and constituted an essential tool in traditional food control. These concepts are still essential in a modern food control system by providing the basic environmental and operating conditions for production of safe food and thus being a requisite or foundation for HACCP in an overall food safety management program. What is new is the concept of formalizing the prerequisite program alongside HACCP and the legal requirement in some countries (USA) of documented monitoring of certain sanitation areas.
Hygiene standards and procedures usually described as Good Hygienic Practices (GHP) or Good Manufacturing Practices (GMP), have been in place for many years and constituted an essential tool in traditional food control. These concepts are still essential in a modern food control system by providing the basic environmental and operating conditions for production of safe food and thus being a requisite or foundation for HACCP in an overall food safety management program. What is new is the concept of formalizing the prerequisite program alongside HACCP and the legal requirement in some countries (USA) of documented monitoring of certain sanitation areas.
Schedule M is good manufacturing practices and requirements of premises, plants and equipment for pharmaceutical products.
Schedule M is a part of drugs and cosmetics act, 1940.
Schedule M- І:Requirements of factory premises for manufacture of homoeopathic preparations.
Schedule M- ІІ: :Requirements of factory premises for manufacture of cosmetics.
Schedule M- ІІІ: :Requirements of factory premises for manufacture of medical devices.
gmp is the most important topic for the students of ayurveda specially for rasashstra.
so in my presentations knowledge of gmp given very elaborately and easy to understand manner.
please advise any suggestions. thank u
This slides contain description about SCHEDULE T good manufacturing process of Indian system of medicine contains about the process of GMP in indian system of medicine...
A detailed study of the organisation and personnel involved in the pharmaceutical industry. These are involved in the guidelines of Good Manufacturing Practices.
Schedule M, M1, M2, M3 are parts of Drugs And Cosmetics Act. Schedule M to M3 Contains Good manufacturing requirements for Drugs. This are formulated to ensure that Drugs intended for human consumption and diagnosis have required safety and efficacy.
Schedule T – Good Manufacturing Practice of Indian systems of medicine
Components of GMP (Schedule – T) and its objectives
Infrastructural requirements, working space, storage area, machinery and equipments,
standard operating procedures, health and hygiene, documentation and records.
INTRODUCTION
Components of GMP
GMP Provisions: Under Schedule-T are grouped
Location and surroundings
Factory Premises
Buildings
Water supply
Containers cleaning
Disposal of Waste
Requirements for the sterile products
store
Working space:
Space requirement for manufacturing of Unani medicine
Health & Hygiene
Machinery and Equipments
Machinery and equipments for maufacturing of ayurveda and siddha medicine
Documentation and Records
Schedule M is good manufacturing practices and requirements of premises, plants and equipment for pharmaceutical products.
Schedule M is a part of drugs and cosmetics act, 1940.
Schedule M- І:Requirements of factory premises for manufacture of homoeopathic preparations.
Schedule M- ІІ: :Requirements of factory premises for manufacture of cosmetics.
Schedule M- ІІІ: :Requirements of factory premises for manufacture of medical devices.
gmp is the most important topic for the students of ayurveda specially for rasashstra.
so in my presentations knowledge of gmp given very elaborately and easy to understand manner.
please advise any suggestions. thank u
This slides contain description about SCHEDULE T good manufacturing process of Indian system of medicine contains about the process of GMP in indian system of medicine...
A detailed study of the organisation and personnel involved in the pharmaceutical industry. These are involved in the guidelines of Good Manufacturing Practices.
Schedule M, M1, M2, M3 are parts of Drugs And Cosmetics Act. Schedule M to M3 Contains Good manufacturing requirements for Drugs. This are formulated to ensure that Drugs intended for human consumption and diagnosis have required safety and efficacy.
Schedule T – Good Manufacturing Practice of Indian systems of medicine
Components of GMP (Schedule – T) and its objectives
Infrastructural requirements, working space, storage area, machinery and equipments,
standard operating procedures, health and hygiene, documentation and records.
INTRODUCTION
Components of GMP
GMP Provisions: Under Schedule-T are grouped
Location and surroundings
Factory Premises
Buildings
Water supply
Containers cleaning
Disposal of Waste
Requirements for the sterile products
store
Working space:
Space requirement for manufacturing of Unani medicine
Health & Hygiene
Machinery and Equipments
Machinery and equipments for maufacturing of ayurveda and siddha medicine
Documentation and Records
Good Manufacturing Practices in Pharmaceutical IndustryMs. Kiran Divekar
GMP is a part of quality assurance which ensures that products are consistently produced and controlled to the quality standards approproiate to their intended use.
It is concerned with both production & quality control.
Product is considered adulterated if GMP is not followed
Quality control measures in pharmaceutical industryChemOnTheGo
QUALITY CONTROL
ROLE OF QUALITY CONTROL IN PHARMACEUTICAL INDUSTRY
OBJECTIVES OF QUALITY CONTROL
STEPS IN QUALITY CONTROL
COST OF QUALITY CONTROL
TOTAL QUALITY MANAGEMENT
QUALITY CIRCLE
Current good manufacturing practice .pptxOsamaTauseef2
Current good manufacturing practice according to Leon Lachman
Helpful contains for al pharmacy students like diploma, degree and also masters of pharmacy students
So use the contains and build your knowledge.
Shock is a critical condition brought on by the sudden drop in blood flow through the body. Shock may result from trauma, heatstroke, blood loss, an allergic reaction, severe infection, poisoning, severe burns or other causes. When a person is in shock, his or her organs aren't getting enough blood or oxygen.
Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Diabetes mellitus, or simply diabetes, is a group of metabolic diseases in which a person has high blood sugar, either because the pancreas does not produce enough insulin, or because cells do not respond to the insulin that is produced. The term diabetes is from the Greek word diabaineine refers a tubular organ that take-in or expels water-excessive urine discharges. In 1675, Thomas Willis added mellitus (means ―honey in Latin) to the word diabetes and called it as Diabetes Mellitus, which refers to too much of sweet taste urine. This high blood sugar produces the classical symptoms of polyuria (frequent urination), polydipsia (increased thirst) and polyphagia (increased hunger). Diabetes mellitus is a disorder of glucose regulation, characterized by an accumulating glucose concentration in the blood (Wilkins and Atanasov, 1996).
The existence of look alike and sound alike drug names is a one of the most common causes of medication error and is of concern worldwide. As more medicines and new brands are being marketed in addition to the thousands already available. Many of these medication names may look or sound alike. Thus, the potential for error due to confusing drug names is very high. According to the survey from United States Pharmacopoeia, around commonly used medications were involved in such errors. Error prone medication pairs that can easily cause confusion while prescribing, dispensing and administration/consumption were sorted out. Also real life experiences of medication errors and near misses due to error prone drug pairs were collected from the doctors and the dispensers. It is very important that we circulate the list of confusing brand names among the practicing doctors, pharmacists and also to the drug manufacturers. Preventing confusion between already marketed products typically involves collecting voluntary reports of names involved in confusion errors, posting warnings and alerts both electronically and in areas where drugs are used. The fear of malpractice lawsuits and public embarrassment has made the physicians and nurses reluctant to report medication errors. It is more important to create the open environment that encourages the reporting of errors than to develop less meaningful comparative error rates. One possible approach to improving medical error reporting systems. This type of system should also enable internal tracking, trending and comparative analyses. We need to have such system in India.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
1. Good Manufacturing Practices
The art of manufacturing
VIR VIKRAM
Associate Professor
Dept. of
Pharmacology
ISF COLLEGE OF PHARMACY
Mobile: +918146023334
Email: virvikram76@gmail.com
3. What is GMP ?
GMP is that part of Quality assurance which ensures that the
products are consistently manufactured and controlled to
the Quality standards appropriate to their intended use
Good Manufacturing Practice is a set of regulations, codes
and guidelines for the manufacture of drug substances and
drug products, medical devices, in vivo and in vitro
diagnostic products and foods.
7. What is cGMP ?
Usually see “cGMP” – where c = current, to emphasize that
the expectations are dynamic
All past GMPs are history….It is looking like in rear view
mirror and driving
8. GLP and GMP
• GMP:
– Protect the integrity and quality of manufactured product intended for human
use.
• GLP:
– Protect the integrity and quality of laboratory data used to support a product
application.
9.
10. Some of the main risks are
1. Unexpected contamination of products, causing damage to health or even
death.
2. Incorrect labels on containers, which could mean that patients receive the
wrong medicine.
3. Insufficient or too much active ingredient, resulting in ineffective treatment or
adverse effects.
11. Good Manufacturing Practices
Worldwide Enforcement
1. Good Manufacturing Practices are enforced in the United States by the
FDA
2. In the United Kingdom by the Medicines and Healthcare Products
Regulatory Agency (MHRA)
3. GMPs are enforced in Australia by the Therapeutically Goods
Administration (TGA)
4. In India by the Ministry of Health (CDSCO)
5. Japan (PDMA), Gulf Countries (GCC), ICH guidelines
6. Many underdeveloped countries lack GMPs
7. The Myanmar Scientific and Technological Research Department (MSTRD)
12. Ten Principles of GMP
1. Design and construct the facilities and equipments properly
2. Follow written procedures and Instructions
3. Document work
4. Validate work
5. Monitor facilities and equipment
6. Write step by step operating procedures and work on instructions
7. Design ,develop and demonstrate job competence
8. Protect against contamination
9. Control components and product related processes
10. Conduct planned and periodic audits
13. Current Good Manufacturing Practices
• Title 21 CFR:
– Part 210: “ . . . In Manufacturing, Processing, Packing, or Holding of Drugs; General”
– Part 211: “ for Finished Pharmaceuticals”
– Part 600: Biologics
– Part 820: Medical Devices
Part 210: General Provisions 210.1 (a)
contain the minimum current good manufacturing practice for methods to be
used in, and the facilities or controls to be used for,
• manufacture,
• processing,
• packing, or holding of a drug
to assure that such drug meets the requirements of the act as to safety, and has the
identity and strength and meets the quality and purity characteristics that it purports
or is represented to possess.”
14. Part 210: General Provisions
210.1 (b)
“The failure to comply with any regulation set forth ... in the manufacture,
processing, packing, or holding of a drug shall render such drug to be adulterated
under section 501(a)(2)(B) of the act and such drug, as well as the person who is
responsible for the failure to comply, shall be subject to regulatory action.”
Part 211: Finished Pharmaceuticals
Subpart A: General Provisions
Subpart B: Organization and Personnel
Subpart C: Buildings and Facilities
Subpart D: Equipment
Subpart E: Control of Components and Drug Product
Containers and Closures
Subpart F: Production and Process Controls
Subpart G: Packaging and Labeling Control
Subpart H: Holding and Distribution
Subpart I: Laboratory Controls
Subpart J: Records and Reports
Subpart K: Returned and Salvaged Drug Products
15. Organization & Personnel
1. Responsibilities of quality control unit.
2. Personnel qualifications.
3. Personnel responsibilities.
4. Consultants.
16. PERSONNEL RESPONSIBILITIES
•Personnel shall wear clean clothing.
•Protective apparel such as head, face, hand and arm coverings
•Protect drug products from contaminations.
•Good sanitation and health habits.
•Only authorized personnel shall enter
•No persons with apparent illness or lesions are allowed to enter
17.
18. HYGIENE AND SANITATION
PRACTICES
*Wash hands with
soap and water
– After using the toilet
– Before starting to work
– After blowing your nose
– After handling dirty things
– After touching body surface
– After eating
19. BUILDINGS AND FACILITIES
DESIGN AND CONSTRUCTION
FEATURES
Buildings should be of adequate
size, construction and location.
Adequate space for orderly
placement of equipment and
materials to prevent mix-ups.
20. BUILDING PREMISES
• GMP REQUIREMENTS:
1. Separate area for specific operation.
2. Easy to clean.
3. Easy to maintain.
4. Easy to operate.
5. Adequate space
6. Eliminate unnecessary traffic
Inadequate space and unnecessary traffic
cause mix-up and errors.
21.
22. Operations should be performed in defined areas of adequate size
(1) Receipt, identification, storage, and withholding from use of
components, drug product containers, closures, and labeling, pending the
appropriate sampling, testing, or examination by the quality control unit
before release for manufacturing or packaging;
(2) Holding rejected components, drug product containers, closures, and
labeling before disposition;
(3) Storage of released components, drug product containers, closures, and
labeling;
23. (4) Storage of in-process materials;
(5) Manufacturing and processing operations;
(6) Packaging and labeling operations;
(7) Quarantine storage before release of drug products;
(8) Storage of drug products after release;
(9) Control and laboratory operations;
(10) Aseptic processing
For injectables should include--Floors, walls, ceilings of smooth, hard surfaces should be
• easily cleanable
• temperature and humidity controls
• filtered air supply, HEPA filters
• system for monitoring environmental conditions
• system for cleaning/disinfecting room/equipment
Types of Protection
•Level 1- General
•Level 2- Protected
•Level 3- Controlled
24. LIGHTING (Adequate lighting shall be provided)
VENTILATION, AIR FILTRATION, AIR HEATING AND COOLING
PLUMBING
25.
26. EQUIPMENT
EQUIPMENT DESIGN,SIZE AND LOCATION
•Appropriate design
•Adequate size
•Suitably located
EQUIPMENT CONSTRUCTION
•Surfaces that contact components, in process materials, drug products shall not be
reactive, additive or absorptive
•Any substances e.g. lubricants, coolants shall not come into contact with components,
containers , closures, in process materials.
EQUIPMENT CLEANING AND MAINTENANCE
•Should be clean and sanitized at appropriate
intervals to prevent contaminations
•Written procedures shall be maintained and
must be followed.
•Records shall be kept of maintenance,
cleaning, sanitizing and inspection.
27. AUTOMATIC,MECHANICALAND
ELECTRONIC EQUIPMENT
•Include computers or related systems
•Should be calibrated
•Written records of calibration checks and
inspection shall be maintained
•Appropriate controls shall be exercised
•Back up file data shall be maintained
•Written records of the program shall be
maintained along with appropriate
validation data
•Hard copy or alternative systems e.g.
duplicates, tapes or microfilms shall be
maintained
28. Control of Components and Drug Product
Containers and Closures
211.80 - General requirements.
211.82 - Receipt and storage of untested components, drug product
containers, and closures.
211.84 - Testing and approval or rejection of components, drug product
containers, and closures.
211.86 - Use of approved components, drug product containers, and
closures.
211.87 - Retesting of approved components, drug product containers, and
closures.
211.89 - Rejected components, drug product containers, and closures.
211.94 - Drug product containers and closures.
29. General requirements
1. There shall be written procedures describing in sufficient detail the
receipt, identification, storage, handling, sampling, testing, and approval
or rejection of components and drug product containers and closures.
2. Components and drug product containers and closures shall at all times
be handled and stored in a manner to prevent contamination.
3. Bagged or boxed components of drug product containers, or closures
shall be stored off the floor and suitably spaced to permit cleaning and
inspection.
4. Each container or grouping of containers for components or drug
product containers, or closures shall be identified with a distinctive code
for each lot in each shipment received.
30. Testing and approval or rejection of components, drug product containers, and
closures
(a)Each lot of components, drug product containers, and closures shall be withheld
from use until the lot has been sampled, tested, or examined, as appropriate, and
released for use by the quality control unit.
(b) Representative samples of each shipment of each lot shall be collected for testing
or examination. The number of containers to be sampled, and the amount of material
to be taken from each container, shall be based upon appropriate criteria.
31. (c) For testing samples shall be collected in accordance with the following procedures:
(1) The containers of components selected shall be cleaned where necessary, by
appropriate means.
(2) The containers shall be opened, sampled, and resealed in a manner designed to
prevent contamination of their own/others.
(3) Sterile equipment and aseptic sampling techniques shall be used when necessary.
(4) Sample containers shall be identified so that the following information can be
determined: name of the material sampled, the lot number, the container from which
the sample was taken, the date on which the sample was taken, and the name of the
person who collected the sample.
(5) Containers from which samples have been taken shall be marked to show that
samples have been removed from them.
32. (d) Samples shall be examined and tested as follows:
(1) At least one test shall be conducted to verify the identity of each component of a
drug product. Specific identity tests, if they exist, shall be used.
(2) Each component shall be tested for conformity with all appropriate written
specifications for purity, strength, and quality.
(3) Containers and closures shall be tested for conformance with all appropriate
written procedures. In lieu of such testing by the manufacturer,
A certificate of testing may be accepted from the supplier
Visual identification is conducted on such containers/closures by the
manufacturer
Manufacturer establishes the reliability of the supplier's test results
through appropriate validation of the supplier's test results at appropriate
Intervals.
33. (4) When appropriate, components shall be microscopically examined.
(5) Each lot of a component, drug product container, or closure that is liable to
contamination with filth, insect infestation, or other extraneous adulterant,
microbiological contamination shall be examined against established specifications
for such contamination.
37. Drug product inspection
a) Packaged and labeled products shall be examined during finishing
operations to provide assurance that containers and packages in the lot have
the correct label.
(b) A representative sample of units shall be collected at the completion of
finishing operations and shall be visually examined for correct labeling.
(c) Results of these examinations shall be recorded in the batch production or
control records.
40. Records and Reports
General requirements
(a) Any production, control, or distribution record that is required to be maintained for
a batch of a drug product shall be retained for at least 1 year after the expiration date of
the batch or, in the case of certain OTC drug products lacking expiration dating 3 years
after distribution of the batch.
(b) Records shall be maintained for all components, drug product containers, closures,
and labeling.
(c) All records or copies of such records, shall be readily available for authorized
inspection during the retention period.
d) Data can be used for evaluating, at least annually, the quality standards of each drug
product to determine the need for changes in drug product specifications or
manufacturing or control procedures.
41. Records and Reports
Equipment cleaning and use log.
Component, drug product container,
closure, and labeling records.
Master production and control
Records.
Batch production and control records.
Production record review.
Laboratory records.
Distribution records.
Complaint files.
42.
43.
44. Equipment cleaning and use log
A written record of major equipment cleaning, maintenance (except routine
maintenance such as lubrication and adjustments), and use shall be included in
individual equipment logs that show
date,
time,
product, and
lot number of each batch processed.
The persons performing and double-checking the cleaning and maintenance shall
date and sign or initial the log indicating that the work was performed.
Entries in the log shall be in chronological order.
45. Master production and control records
a) To assure uniformity from batch to batch
b) Prepared, dated, and signed by one person and independently checked, dated, and
signed by a second person.
c) Master production and control records shall include:
(1) The name and strength of the product and a description of the dosage form;
(2) The name and measure of each active ingredient per dosage unit or per unit of
weight or measure of the drug product, and a statement of the total weight or
measure of any dosage unit;
46. (3) A complete list of components designated by names or codes sufficiently specific
to indicate any special quality characteristic;
(4) An accurate statement of the weight or measure of each component
(5) A statement concerning any calculated excess of component;
(6) A statement of theoretical yield, including the maximum and minimum percentages
of theoretical yield
(7) A description of the drug product containers, closures, and packaging materials,
including a specimen or copy of each label and all other labeling signed and dated by
the person or persons responsible for approval of such labeling;
(9) Complete manufacturing and control instructions, sampling and testing procedures,
specifications, special notations, and precautions to be followed.
47.
48. Component, drug product container, closure, and labeling records
Batch control & Performance recording
Production record review
Laboratory records